BCG vaccination in South African HIV-exposed infants - risks and benefits

Simple item page
dc.contributor.authorHesseling, A C
dc.contributor.authorCaldwell, J
dc.contributor.authorCotton, M F
dc.contributor.authorEley, B S
dc.contributor.authorJaspan, H B
dc.contributor.authorJennings, K
dc.contributor.authorMarais, B J
dc.contributor.authorNuttall, J
dc.contributor.authorRabie, H
dc.contributor.authorRoux, P
dc.contributor.authorSchaaf, H S
dc.date.accessioned2017-04-12T06:59:12Z
dc.date.available2017-04-12T06:59:12Z
dc.date.issued2009
dc.date.updated2016-01-07T08:56:49Z
dc.description.abstractUntil 2007, the World Health Organization (WHO) recommended that bacille Calmette-Guérin (BCG) vaccination should be contraindicated in infants with symptomatic HIV disease in countries with a high burden of tuberculosis. This recommendation was based on the perceived low risk of serious adverse events in HIV-infected infants. The WHO revised its recommendations regarding BCG vaccination in HIV-infected infants in 2007, making HIV infection a full contraindication to BCG vaccination. BCG induces protective efficacy against tuberculous meningitis of 73% (67 - 79%) and against miliary disease of 77% (58 - 87%) in HIV-uninfected children. The efficacy against childhood pulmonary disease is variable;3 there is no evidence that BCG induces a protective effect against tuberculosis in HIV-infected infants and children. BCG is a safe vaccine in immunocompetent infants, and severe vaccine adverse events in HIV-uninfected infants occur only with rare primary immune deficiencies in approximately 1 per million vaccinees.
dc.identifierhttp://dx.doi.org/10.7196/SAMJ.3163
dc.identifier.apacitationHesseling, A. C., Caldwell, J., Cotton, M. F., Eley, B. S., Jaspan, H. B., Jennings, K., ... Schaaf, H. S. (2009). BCG vaccination in South African HIV-exposed infants - risks and benefits. <i>South African Medical Journal</i>, http://hdl.handle.net/11427/24184en_ZA
dc.identifier.chicagocitationHesseling, A C, J Caldwell, M F Cotton, B S Eley, H B Jaspan, K Jennings, B J Marais, et al "BCG vaccination in South African HIV-exposed infants - risks and benefits." <i>South African Medical Journal</i> (2009) http://hdl.handle.net/11427/24184en_ZA
dc.identifier.citationHesseling, A. C., Caldwell, J., Cotton, M. F., Eley, B. S., Jaspan, H. B., Jennings, K., . . . Schaaf, H. S. (2009). BCG vaccination in south african HIV-exposed infants - risks and benefits : Issues in public health : SAMJ forum. South African Medical Journal, 99(2), 88-91.
dc.identifier.ris TY - Journal Article AU - Hesseling, A C AU - Caldwell, J AU - Cotton, M F AU - Eley, B S AU - Jaspan, H B AU - Jennings, K AU - Marais, B J AU - Nuttall, J AU - Rabie, H AU - Roux, P AU - Schaaf, H S AB - Until 2007, the World Health Organization (WHO) recommended that bacille Calmette-Guérin (BCG) vaccination should be contraindicated in infants with symptomatic HIV disease in countries with a high burden of tuberculosis. This recommendation was based on the perceived low risk of serious adverse events in HIV-infected infants. The WHO revised its recommendations regarding BCG vaccination in HIV-infected infants in 2007, making HIV infection a full contraindication to BCG vaccination. BCG induces protective efficacy against tuberculous meningitis of 73% (67 - 79%) and against miliary disease of 77% (58 - 87%) in HIV-uninfected children. The efficacy against childhood pulmonary disease is variable;3 there is no evidence that BCG induces a protective effect against tuberculosis in HIV-infected infants and children. BCG is a safe vaccine in immunocompetent infants, and severe vaccine adverse events in HIV-uninfected infants occur only with rare primary immune deficiencies in approximately 1 per million vaccinees. DA - 2009 DB - OpenUCT DP - University of Cape Town J1 - South African Medical Journal LK - https://open.uct.ac.za PB - University of Cape Town PY - 2009 T1 - BCG vaccination in South African HIV-exposed infants - risks and benefits TI - BCG vaccination in South African HIV-exposed infants - risks and benefits UR - http://hdl.handle.net/11427/24184 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/24184
dc.identifier.vancouvercitationHesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, Jennings K, et al. BCG vaccination in South African HIV-exposed infants - risks and benefits. South African Medical Journal. 2009; http://hdl.handle.net/11427/24184.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Paediatrics and Child Healthen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.sourceSouth African Medical Journal
dc.source.urihttp://www.samj.org.za/index.php/samj
dc.titleBCG vaccination in South African HIV-exposed infants - risks and benefits
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hesseling_BCG_vaccination_in_South_2009.pdf
Size:
147.69 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles